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ABSTRACT 25 
The careHPV and HC2 assays were compared for high-risk HPV (HR-HPV) DNA 26 
detection in cervical samples from 149 HIV-1-infected African women. HR-HPV DNA 27 
detection rate was 37.6% and 34.9% by careHPV and HC2, respectively. Agreement 28 
between the two tests was 94.6% (95% CI, 89.7%-97.7%) with a Kappa value of 0.88, 29 
(95% CI, 0.81-0.96) indicating an excellent agreement. CareHPV may be considered as 30 
suitable as HC2 for cervical cancer screening among HIV-infected African women.  31 
 32 
 33 
Cervical cancer is the third most common cancer in women worldwide, with more than 34 
500,000 annual cases, and the fourth most common cause of cancer death in women, with 35 
about 275,000 annual deaths. However, more than 85% of cases and deaths occur in 36 
developing countries, cervical cancer being the commonest cancer and the leading cause of 37 
cancer death in African women (Globocan 2008, http://globocan.iarc.fr). The high mortality 38 
rate observed in Africa is mainly due to the absence of cervical cancer screening, resulting in 39 
diagnosis of advanced and often untreatable disease (1).  40 
Virtually, all cases of cervical cancer result from persistent infection with carcinogenic 41 
genotypes of human papillomavirus (HPV) (2). It is now well established that detection of 42 
these high-risk HPV (HR-HPV) genotypes in cervical samples allows to identify women at 43 
risk of precancerous or cancerous cervical lesions, and HR-HPV DNA  testing has been 44 
proposed as a primary screening test for cervical cancer prevention (3, 4). 45 
Incidence of HR-HPV infection and of high-grade cervical lesions is significantly increased in 46 
women infected with HIV-1 (5-7). Therefore, a screening strategy based on HR-HPV testing 47 
in African women infected with HIV-1 may play an important role in cervical cancer 48 
prevention.  49 
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The Hybrid Capture 2 (HC2) assay (Qiagen Corporation, Gaithersburg, MD) is a Food and 50 
Drug Administration (FDA)-approved test for cervical cancer screening. This assay is based 51 
on HR-HPV detection using a cocktail of RNA probes targeting 13 HR-HPV types, namely 52 
HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, 53 
HPV58, HPV59, and HPV68. The careHPV assay (Qiagen) is a new signal-amplification 54 
assay adapted from HC2. This assay, which  is designed to be simpler and more rapid to use, 55 
and more affordable than HC2 in resource-poor settings, targets 14 HR-HPV types, HPV66 56 
being included in the probe cocktail in addition to the 13 HR-HPV types targeted by the HC2 57 
assay (8, 9). There has been no published evaluation of the direct comparison between the two 58 
assays.  59 
We compared the careHPV assay with the HC2 assay in a subset of women enrolled in the 60 
HARP (HPV in Africa Research Partnership) study, which is conducted in two Sub-Saharan 61 
African countries, South Africa and Burkina Faso, with the aim to evaluate cervical cancer 62 
screening and treatment approaches for the prevention of cervical neoplasia in HIV-1 infected 63 
African women. Over 1200 consenting HIV-1 seropositive women aged 25-50, of whom two-64 
thirds were on ART, were enrolled in the HARP study between November 2011 and October 65 
2012 and followed up at 6 monthly intervals for 18 months. The study was approved by the 66 
research ethics committees of the University of the Witwatersrand in South Africa, the 67 
Ministry of Health in Burkina Faso, and the London School of Hygiene & Tropical Medicine.   68 
The comparison was done on samples collected from 149 unselected consecutive HARP study 69 
participants (75 in Johannesburg, South Africa and 74 in Ouagadougou, Burkina Faso) 70 
attending their regular research clinic appointment 12 months after enrolment, between 71 
February and April 2013. At baseline visit, 68 (46%) women were 25-34 years old and 81 72 
(54%) were 35-50 years old, and 48 (32%) had a CD4+ T cell count  350 cells/µl. 73 
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Two cervical samples were consecutively taken for each woman. The first sample was 74 
collected using the careHPV sample collection device consisting of a careBrush and a vial of 75 
careHPV collection medium. The second sample was collected using the Digene cervical 76 
sampler consisting of a cervical brush and Specimen Transport Medium. CareHPV tests were 77 
performed in the respective sites by medical scientists specifically trained by a Qiagen's 78 
scientist and the HC2 tests were performed in Montpellier, France, on samples stored at -80°C 79 
and shipped in dry ice.  The assays were performed according to the Manufacturer's 80 
instructions. The HC2 assay was considered positive when the relative light unit/cutoff 81 
(RLU/CO) ratio was ≥ 1. The positive or negative result of the careHPV assay was displayed 82 
by the careHPV test controller without additional specification of the luminescent signal 83 
intensity. Samples for which a discrepant result between the two assays was observed were 84 
tested for HPV detection and typing using the INNO-LiPA HPV genotyping Extra assay 85 
(Innogenetics, Courtaboeuf, France). In case of non-typable HPV as identified by the INNO-86 
LiPA HPV genotyping Extra assay, genotyping was performed by sequencing as previously 87 
described (10).  88 
The HR-HPV prevalence was 37.6% (95% CI, 29.8%-45.9%) by careHPV and 34.9% (95% 89 
CI, 27.3%-43.1%) by HC2. In South Africa, prevalence of HR-HPV was 37.3% by careHPV 90 
and 33.3% by HC2, whereas in Burkina Faso, this prevalence was 37.8% by careHPV and 91 
36.5% by HC2. The overall agreement between tests was 94.6% (141/149, 95% CI, 89.7%-92 
97.7%) (Table 1). Agreement was 96.0% (72/75; 95% CI, 88.8%-99.2%) in South Africa and 93 
93.2% (69/74; 95% CI, 84.9%-97.8%) in Burkina Faso. The Kappa test value of 0.88 (95% 94 
CI, 0.81-0.96) indicated an excellent agreement. The results obtained for the discrepant 95 
samples are shown in Table 2. All the discrepant samples were positive for HPV detection by 96 
the INNO-LiPA HPV genotyping Extra assay. Among the six samples positive by careHPV 97 
and negative by HC2, five were positive for HR-HPV types targeted by HC2 probes and one 98 
 5 
 
5
was positive for HPV25, a non-HR-HPV type. Among the two samples negative by careHPV 99 
and positive by HC2 one was positive for the HR-type HPV51 and the other was only positive 100 
for the low-risk type HPV6.  101 
Taken together these results indicate an excellent agreement between the careHPV and HC2 102 
assays. The few cases of discrepancy observed may be due to amounts of HR-HPV DNA at 103 
the limit of detectability or to cross-reactivity with non-HR-HPV types (11). Moreover, the 104 
fact that the two assays were not performed on the same sample but on consecutive samples 105 
collected in the assay-specific collection medium may have been a cause of discrepancy, 106 
independently from the performances of the assays themselves. Results from this study 107 
indicate that careHPV may be considered as suitable as HC2 for cervical cancer screening 108 
among HIV-infected women in resource-constrained settings. 109 
 110 
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TABLE 1: Agreement between the careHPV and HC2 assays among 149 HIV-positive 177 
women from Burkina Faso and South Africa.   178 
 179 
 180 
 181 
 182 
 183 
            P < 0.0001 (McNemar's test) 184 
185 
 careHPV 
HC2 Positive Negative 
Positive 50 (33.6%) 2 (1.3%) 
Negative 6 (4.0%) 91 (61.1%) 
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TABLE 2. Results obtained for 8 samples with discrepant results between careHPV and HC2. 186 
 187 
 
Sample No. 
 
Country
a 
 
CareHPV 
 
HC2 
HC2 
RLU/CO
 
Genotyping 
S253 SA Positive Negative 0.50 HPV11, HPV16, HPV18 
S295 SA Positive Negative 0.16 HPV68 
S604 SA Positive Negative 0.43 HPV52, HPV68, HPV73 
B231 BF Positive Negative 0.27 HPV35 
B292 BF Positive Negative 0.26 HPV52 
B304 BF Positive Negative 0.19 HPV25
b
 
B331 BF Negative Positive 5.07 HPV6 
B393 BF Negative Positive 10.38 HPV51, HPV69/71
c
, HPV70
a
 SA, South Africa; BF, Burkina Faso 188 
b
Identified by sequencing 189 
c
No discrimination between HPV69 and HPV71 by the INNO-LiPA HPV genotyping Extra 190 
assay. 191 
